News

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study aimed at evaluating the activating effects of Lipiodol®-based conventional transarterial chemoembolization (cTACE) on the immunity of patients with hepatocellular carcinoma (HCC)

▪ HCC is the second leading cause of cancer mortality worldwide

▪ Evaluation of the immunogenic potential of cTACE

We use cookies to improve your website experience and to gain insights into our websites’ users and traffic to make it even better. By continuing your navigation on our site without modifying the setting of your cookies, you accept the use of cookies. OKFind out more